We will investigate the clinical manifestations and molecular genetic defects of heritable urologic malignant disorders. Families with urologic malignancy with…

Kidney CancerUrologic Malignant DisordersRenal Cell Carcinoma+2 more

~Estimated

~$10 – $675

National Cancer Institute (NCI)NCT00001238

Phase 2

A Phase II Study of Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases in Patients Previously Treated With Immune Checkpoint Inhibitors

This is a single-institution, phase 2 trial of zanzalintinib plus investigator-choice bone-strengthening agent in patients with metastatic renal cell carcinoma…

Clear Cell Renal Cell Cancer (ccRCC)Clear Cell Renal CarcinomaClear Cell Renal Cell Carcinoma Metastatic+7 more

~Estimated

~$10 – $7,500

Kelly Fitzgerald, MDNCT07043608